Seismic Therapeutic

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Seismic Therapeutic Closes $121 Million Series B Financing to Advance Immunology Pipeline Optimized by its Machine Learning Platform

Details:

The net proceeds will be used to advance through Phase 1 proof-of-mechanism trials with Seismic’s two lead programs, a pan‑immunoglobulin G protease sculpting enzyme candidate, S-1117 and a PD-1 agonist:Fc gamma receptor IIb selective DcB antibody candidate, S-4321.

Lead Product(s): S-1117

Therapeutic Area: Immunology Product Name: S-1117

Highest Development Status: IND EnablingProduct Type: Large molecule

Partner/Sponsor/Collaborator: Bessemer Venture Partners

Deal Size: $21.0 million Upfront Cash: Undisclosed

Deal Type: Series B Financing December 04, 2023

ASK
US

Upload
your Marketing & Sales content

Seismic Therapeutic

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Seismic Therapeutic Launches with $101 Million Series A Financing to Usher in a New Era of Immunology Drug Development Integrating Machine Learning

Details:

The Series A financing will support Seismic Therapeutic’s further advancement toward the clinic of its first two lead drug programs, one targeting Ig (immunoglobulin)-mediated autoimmunity and the other targeting cell-mediated autoimmunity.

Lead Product(s): Undisclosed

Therapeutic Area: Immunology Product Name: Undisclosed

Highest Development Status: Discovery PlatformProduct Type: Large molecule

Partner/Sponsor/Collaborator: Lightspeed Venture Partners

Deal Size: $101.0 million Upfront Cash: Undisclosed

Deal Type: Series A Financing February 09, 2022

ASK
US

Upload
your Marketing & Sales content